



Marksans Pharma Ltd.

Date: April 15, 2024

BSE Limited

Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai - 400001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.

Scrip Code: 524404

Symbol: MARKSANS

Sub: Disclosure pursuant to Chapter XII of the Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021

Dear Sir/Madam,

Pursuant to Chapter XII of the Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as amended from time to time, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, on fund raising by issuance of debt securities by large corporate, kindly find enclosed **Annexure A**, an initial disclosure to be made by the Company for FY2024-2025.

We request you to take the aforesaid on records.

Thanking you,

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Encl: as above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com

www.marksanspharma.com



Marksans Pharma Ltd.

Annexure A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1.	Name of the Company	Marksans Pharma Limited
2.	CIN	L24110MH1992PLC066364
3.	Outstanding borrowing of company as on 31 st March, 2024 (in Rs. Cr.)	Nil
4.	Highest Credit Rating during the previous FY along with name of the Credit Rating Agency	India Ratings and Research Private Limited IND A+/Positive & IND A1+ CARE A+; Stable & CARE A1+
5.	Name of Stock Exchange in which the fine shall be paid in case of shortfall in the required borrowing under the framework	National Stock Exchange of India Limited

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as amended.

Harshavardhan Panigrahi
Company Secretary
Contact details: 022 40012000
E-mail: harshavardhan@marksanspharma.com



Jitendra Sharma
Chief Financial Officer
Contact details: 022 40012000
E-mail: jitendra@marksanspharma.com

Date: April 15, 2024

**In terms paragraph of 2.2(d) of the circular, beginning FY2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of stock exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.*

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 052 • Tel: +91 22 4001 2000 • E-mail: info@marksanspharma.com